[PUBLICATION] Therapeutic news in ALS

  • Recherche,
  • Santé-Sciences-Technologie,
  • Santé-social,

le 28 mai 2021

Published in Rev Neurol

Collaborative research project led by Prof. Couratier (Fédération des Centres SLA De Tours et Limoges, LITORALS; Centre Constitutif de référence SLA, CHU de Limoges, 2, avenue Martin Luther King, 87000 Limoges, France) in which Prof. Corcia participated

Therapeutic news in ALS


Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by death of motor neurons in the cortex and the spinal cord. This loss of motor neurons causes progressive weakness and amyotrophy. To date, the median duration of survival in patients with ALS, from first symptoms to death, is estimated to be 36 months. Currently the treatment is limited to two options: riluzole which prolongs survival for a few months and edaravone which is available in only a few countries and also has a small impact on disease progression. There is an urgent need for more effective drugs in this disease to significantly improve progression. Over the last 30 years, all trials have failed to find a curative drug for ALS. This is due, partially, to the heterogeneity of the clinical features and the pathophysiology of motor neuron death. We present in this review the various treatment options currently being developed for ALS, with an emphasis on the range of therapeutic approaches being explored, from old drugs tested in a new indication to innovative drugs obtained via biotechnology or gene therapy.


Amyotrophic Lateral Sclerosis; Therapeutic-clinical trials.

Contact :
Prof. Philippe Corcia :